Page 8 - வெற்றி புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
2021 Bulloch Valedictorians - Statesboro Herald
statesboroherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statesboroherald.com Daily Mail and Mail on Sunday newspapers.
Statesboro: KEVIN DAVOUD - Statesboro Herald
statesboroherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statesboroherald.com Daily Mail and Mail on Sunday newspapers.
Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer
Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years
May 25, 2021 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose treatment integrated Axumin PE
(0)
- Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years -
- Winship Cancer Institute of Emory University s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose t
May 24, 2021 healthcare
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.
“Patients with EGFR Exon20 insertion+ mNSCLC have no proven targeted therapy options,” said Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University. “The updated r
vimarsana © 2020. All Rights Reserved.